See more : Vision International Holdings Limited (8107.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Sino Biopharmaceutical Limited (SBMFF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sino Biopharmaceutical Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Gala Global Products Limited (GGPL.BO) Income Statement Analysis – Financial Results
- Texmaco Rail & Engineering Limited (TEXRAIL.NS) Income Statement Analysis – Financial Results
- Hangzhou Oxygen Plant Group Co.,Ltd. (002430.SZ) Income Statement Analysis – Financial Results
- CMX Gold & Silver Corp. (CXC.CN) Income Statement Analysis – Financial Results
- Nang Kuang Pharmaceutical Co., Ltd. (1752.TW) Income Statement Analysis – Financial Results
Sino Biopharmaceutical Limited (SBMFF)
About Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.20B | 28.78B | 26.86B | 23.65B | 24.23B | 20.89B | 14.82B | 14.17B | 12.18B | 9.90B | 7.74B | 6.70B | 4.68B | 3.48B | 2.86B | 2.01B | 1.09B | 736.64M | 787.02M | 1.12B | 876.12M | 734.72M | 572.98M | 416.85M | 325.52M |
| Cost of Revenue | 4.99B | 5.80B | 5.33B | 5.18B | 4.93B | 4.20B | 3.09B | 2.95B | 2.72B | 2.34B | 1.74B | 1.39B | 1.01B | 668.88M | 563.17M | 416.69M | 192.76M | 139.16M | 145.13M | 198.50M | 179.87M | 154.18M | 107.65M | 88.22M | 87.47M |
| Gross Profit | 21.21B | 22.98B | 21.53B | 18.46B | 19.31B | 16.69B | 11.73B | 11.22B | 9.46B | 7.56B | 6.00B | 5.32B | 3.67B | 2.81B | 2.29B | 1.59B | 897.93M | 597.47M | 641.90M | 920.58M | 696.25M | 580.54M | 465.33M | 328.63M | 238.05M |
| Gross Profit Ratio | 80.95% | 79.86% | 80.15% | 78.08% | 79.67% | 79.91% | 79.14% | 79.20% | 77.67% | 76.41% | 77.49% | 79.32% | 78.50% | 80.79% | 80.28% | 79.26% | 82.33% | 81.11% | 81.56% | 82.26% | 79.47% | 79.01% | 81.21% | 78.84% | 73.13% |
| Research & Development | 4.47B | 4.33B | 3.75B | 2.63B | 2.40B | 2.09B | 1.60B | 1.37B | 1.10B | 863.13M | 695.55M | 435.36M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.87B | 2.20B | 2.19B | 2.66B | 2.59B | 2.19B | 986.95M | 1.09B | 1.03B | 659.68M | 498.78M | 586.12M | 2.47B | 1.89B | 367.02M | 1.04B | 144.93M | 122.13M | 115.40M | 168.46M | 123.91M | 89.42M | 83.42M | 58.29M | 44.23M |
| Selling & Marketing | 9.19B | 10.36B | 10.52B | 8.97B | 9.32B | 8.08B | 5.92B | 5.71B | 4.94B | 4.27B | 3.45B | 2.95B | 0.00 | 0.00 | 1.13B | 0.00 | 471.91M | 328.60M | 323.32M | 438.30M | 360.86M | 328.39M | 252.15M | 173.57M | 120.12M |
| SG&A | 11.07B | 12.56B | 12.70B | 11.63B | 11.91B | 10.27B | 6.90B | 6.79B | 5.97B | 4.93B | 3.95B | 3.53B | 2.47B | 1.89B | 1.50B | 1.04B | 616.84M | 450.74M | 438.73M | 606.76M | 484.77M | 417.81M | 335.58M | 231.86M | 164.35M |
| Other Expenses | 0.00 | 4.38B | 4.48B | -94.52M | -90.96M | 35.84M | 30.56M | 33.39M | 17.89M | 23.29M | 12.92M | 20.82M | 383.51M | -9.13M | 86.59M | 15.40M | -50.35M | -31.34M | -42.10M | 52.39M | 6.15M | -1.19M | -2.03M | -2.63M | 4.36M |
| Operating Expenses | 15.42B | 16.95B | 17.19B | 14.16B | 14.22B | 12.37B | 8.47B | 8.33B | 7.08B | 5.74B | 4.62B | 3.97B | 2.86B | 1.88B | 1.59B | 1.06B | 600.87M | 359.00M | 482.68M | 648.39M | 527.62M | 435.46M | 338.45M | 235.13M | 168.71M |
| Cost & Expenses | 20.53B | 22.74B | 22.52B | 19.34B | 19.14B | 16.57B | 11.56B | 11.28B | 9.80B | 8.07B | 6.36B | 5.36B | 3.86B | 2.55B | 2.15B | 1.47B | 793.63M | 498.17M | 627.81M | 846.89M | 707.49M | 589.64M | 446.09M | 323.35M | 256.18M |
| Interest Income | 186.68M | 201.44M | 162.06M | 194.00M | 257.71M | 162.72M | 83.06M | 40.67M | 78.13M | 90.83M | 53.55M | 50.64M | 29.92M | -0.88 | -0.92 | -0.24 | 76.14M | 80.87M | -0.48 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 495.24M | 439.06M | 308.62M | 323.37M | 229.95M | 153.26M | 77.95M | 80.20M | 66.83M | 34.46M | 1.95M | 7.77M | 9.14M | 4.95M | 2.44M | 8.04M | 2.41M | 2.21M | 2.84M | 60.95M | 56.76M | 65.97M | 52.68M | 38.07M | 28.41M |
| Depreciation & Amortization | 1.07B | 1.05B | 992.56M | 1.65B | 1.47B | 1.18B | 343.39M | 353.09M | 295.85M | 207.50M | 174.99M | 154.55M | 110.02M | 73.01M | 53.06M | 36.58M | 27.13M | 22.10M | 30.59M | 34.61M | 27.41M | 14.54M | -50.65M | -35.44M | -24.45M |
| EBITDA | 6.98B | 6.69B | 19.87B | 6.54B | 7.37B | 6.15B | 4.62B | 3.60B | 3.25B | 2.48B | 1.85B | 1.54B | 925.06M | 1.00B | 759.40M | 573.16M | 350.22M | 229.94M | 189.80M | 306.80M | 196.03M | 159.63M | 140.76M | 92.96M | 69.34M |
| EBITDA Ratio | 26.64% | 26.88% | 73.91% | 27.67% | 30.02% | 29.44% | 30.49% | 26.69% | 26.43% | 24.71% | 23.47% | 23.61% | 19.77% | 28.85% | 26.59% | 28.52% | 32.11% | 31.21% | 24.12% | 27.42% | 22.38% | 21.73% | 22.14% | 22.43% | 21.30% |
| Operating Income | 5.79B | 6.69B | 18.86B | 4.89B | 5.81B | 4.97B | 4.17B | 4.71B | 2.68B | 2.01B | 2.20B | 1.45B | 815.03M | 932.97M | 705.52M | 536.58M | 373.24M | 238.47M | 159.22M | 283.21M | 178.56M | 145.08M | 126.89M | 93.50M | 93.79M |
| Operating Income Ratio | 22.08% | 23.25% | 70.21% | 20.67% | 23.97% | 23.81% | 28.17% | 33.27% | 21.98% | 20.26% | 28.37% | 21.58% | 17.42% | 26.79% | 24.70% | 26.70% | 34.22% | 32.37% | 20.23% | 25.31% | 20.38% | 19.75% | 22.14% | 22.43% | 28.81% |
| Total Other Income/Expenses | -375.81M | -370.96M | 14.22B | 124.65M | -224.50M | 7.11B | 21.41M | 342.42M | 486.87M | 234.85M | 318.95M | -59.80M | -9.14M | -6.16M | -1.62M | -8.04M | -52.56M | -32.84M | -42.10M | -125.01M | 6.15M | -1.19M | -2.03M | -3.17M | -3.96M |
| Income Before Tax | 5.41B | 5.78B | 18.57B | 5.01B | 5.58B | 11.43B | 4.20B | 3.35B | 2.88B | 2.24B | 1.67B | 1.44B | 805.90M | 926.81M | 703.90M | 528.53M | 320.68M | 205.63M | 117.12M | 335.60M | 184.71M | 143.89M | 124.86M | 90.86M | 65.38M |
| Income Before Tax Ratio | 20.65% | 20.08% | 69.14% | 21.20% | 23.04% | 54.71% | 28.31% | 23.65% | 23.67% | 22.63% | 21.58% | 21.48% | 17.22% | 26.61% | 24.65% | 26.30% | 29.40% | 27.91% | 14.88% | 29.99% | 21.08% | 19.58% | 21.79% | 21.80% | 20.08% |
| Income Tax Expense | 797.27M | 775.99M | 1.96B | 672.38M | 889.45M | 696.24M | 542.29M | 496.97M | 446.22M | 351.96M | 277.05M | 299.12M | 134.77M | 194.43M | 118.89M | 104.13M | 31.82M | 22.17M | 19.06M | 31.90M | 24.84M | 18.23M | 8.69M | 7.17M | 2.78M |
| Net Income | 2.33B | 5.00B | 14.61B | 4.34B | 4.69B | 9.05B | 2.17B | 1.71B | 1.49B | 1.21B | 810.13M | 717.23M | 374.56M | 483.12M | 349.50M | 262.05M | 210.17M | 141.55M | 1.72B | 179.35M | 87.02M | 60.88M | 65.52M | 48.26M | 38.15M |
| Net Income Ratio | 8.90% | 17.38% | 54.38% | 18.36% | 19.37% | 43.31% | 14.65% | 12.09% | 12.22% | 12.22% | 10.47% | 10.70% | 8.00% | 13.87% | 12.24% | 13.04% | 19.27% | 19.22% | 218.58% | 16.03% | 9.93% | 8.29% | 11.43% | 11.58% | 11.72% |
| EPS | 0.08 | 0.27 | 0.78 | 0.23 | 0.25 | 0.49 | 0.13 | 0.10 | 0.09 | 0.07 | 0.05 | 0.04 | 0.02 | 0.03 | 0.02 | 0.02 | 0.01 | 0.01 | 0.11 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 |
| EPS Diluted | 0.10 | 0.26 | 0.73 | 0.23 | 0.25 | 0.49 | 0.13 | 0.10 | 0.09 | 0.07 | 0.05 | 0.04 | 0.02 | 0.03 | 0.02 | 0.02 | 0.01 | 0.01 | 0.11 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 |
| Weighted Avg Shares Out | 23.39B | 18.62B | 18.77B | 18.80B | 18.81B | 18.55B | 16.68B | 16.68B | 16.68B | 16.68B | 16.68B | 16.68B | 16.71B | 16.38B | 15.28B | 15.28B | 15.28B | 15.28B | 14.91B | 13.49B | 13.44B | 3.07B | 3.03B | 2.59B | 2.44B |
| Weighted Avg Shares Out (Dil) | 18.53B | 19.02B | 19.28B | 18.80B | 18.81B | 18.55B | 16.68B | 16.68B | 16.68B | 16.68B | 16.68B | 16.68B | 16.71B | 16.38B | 15.28B | 15.28B | 15.28B | 15.28B | 14.91B | 14.67B | 14.81B | 3.44B | 3.22B | 2.59B | 2.44B |
Sino Biopharmaceutical to divest 67% stake in unit CP Qingdao for $253 mln
Chinese Company Gets FDA Approval For Drug To Fight Chemotherapy Nausea
Source: https://incomestatements.info
Category: Stock Reports